CELL INTELLIGENCE · 肿瘤细胞治疗研究

T 细胞动力学、CD8/NK 比值及肿瘤生存特征决定骨髓瘤对 T 细胞双特异性抗体 forimtamig 的应答

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

靶向 GPRC5D 的免疫治疗在复发/难治性多发性骨髓瘤中的最新进展：2022 ASH 年会更新

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.

通过单细胞测序鉴定复发/难治性多发性骨髓瘤中 BCMA CAR-T 治疗后复发的潜在耐药机制和治疗靶点

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myelom

多发性骨髓瘤 CAR-NK 细胞治疗的最新进展：细胞来源与靶抗原的综合综述

State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.

利用 CAR-NK 细胞对抗多发性骨髓瘤：当前格局与未来方向

Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.

CAR-NK 疗法正从一种有前景的概念演变为针对 MM 的现实治疗平台。

多发性骨髓瘤当前的新型靶向治疗策略

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

G 蛋白偶联受体 C 类 5 组成员 D 靶向免疫治疗在多发性骨髓瘤中的新兴作用：进展、耐药与联合策略

Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination

多发性骨髓瘤细胞治疗的新方法：聚焦 CAR-T 细胞

Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells.

CAR-T 细胞疗法在多发性骨髓瘤治疗中显示出显著获益。

双特异性抗体治疗复发/难治性多发性骨髓瘤：更新与未来展望

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.